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Abstract
Background: While inferior to oxytocin injection in both efficacy and safety, orally administered misoprostol has
been included in the World Health Organization Model List of Essential Medicines for use in the prevention of
postpartum haemorrhage (PPH) in low-resource settings. This study evaluates the costs and health outcomes of use
of oral misoprostol to prevent PPH in settings where injectable uterotonics are not available.
Methods: A cost-consequences analysis was conducted from the international health system perspective, using
data from a recent Cochrane systematic review and WHO’s Mother-Baby Package Costing Spreadsheet in a
hypothetical cohort of 1000 births in a mixed hospital (40 % births)/community setting (60 % births). Costs were
estimated based on 2012 US dollars.
Results: Using oxytocin in the hospital setting and misoprostol in the community setting in a cohort of 1000 births,
instead of oxytocin (hospital setting) and no treatment (community setting), 22 cases of PPH could be prevented.
Six fewer women would require additional uterotonics and four fewer women a blood transfusion. An additional
130 women would experience shivering and an extra 42 women fever. Oxytocin/misoprostol was found to be cost
saving (US$320) compared to oxytocin/no treatment.
If misoprostol is used in both the hospital and community setting compared with no treatment (i.e. oxytocin not
available in the hospital setting), 37 cases of PPH could be prevented; ten fewer women would require additional
uterotonics; and six fewer women a blood transfusion. An additional 217 women would experience shivering and
70 fever. The cost savings would be US$533.
Sensitivity analyses indicate that the results are sensitive to the incidence of PPH-related outcomes, drug costs and
the proportion of hospital births.
Conclusions: Our findings confirm that, even though misoprostol is not the optimum choice in the prevention of
PPH, misoprostol could be an effective and cost-saving choice where oxytocin is not or cannot be used due to a
lack of skilled birth attendants, inadequate transport and storage facilities or where a quality assured oxytocin
product is not available. These benefits need to be weighed against the large number of additional side effects
such as shivering and fever, which have been described as tolerable and of short duration.
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Background
Postpartum haemorrhage (PPH) continues to be a lead-
ing cause of maternal deaths, particularly in low-income
countries [1, 2]. Almost one-third of maternal deaths
worldwide are due to haemorrhage, mostly in the post-
partum period [3]. It is therefore recommended that ac-
tive management of the third stage of labour (AMTSL)
be offered to all women during childbirth by a skilled at-
tendant to prevent PPH [4]. WHO guidelines for
AMTSL include prophylactic administration of a utero-
tonic soon after the birth of the baby, delivery of the pla-
centa by controlled cord traction (where skilled birth
attendants are available) and late cord clamping (per-
formed after 1 to 3 min after birth) [4]. The latter is not
recommended in all guidelines [5]. Even with these ef-
forts to prevent PPH, some women will require
treatment for excessive bleeding and timely interven-
tions including use of additional uterotonics by skilled
providers [6].
Drugs that can be used for PPH prophylaxis include
oxytocin (intravenous (IV) or intramuscular (IM)); syn-
tometrine (IM); ergometrine (IV or IM) and oral miso-
prostol [7]. The gold standard treatment for the
prevention of PPH is 10 iU oxytocin, recommended by
the World Health Organization (WHO), the Inter-
national Federation of Gynecology and Obstetrics and
International Confederation of Midwives [4, 5]. However,
widespread use of oxytocin is impeded by its need for
cold-chain storage and either intravenous or intramus-
cular administration by a skilled birth attendant. In the
world’s least developed countries it is estimated that only
35 % of births are attended by skilled health workers [8].
While new aerosol formulations of oxytocin are being
developed that do not require skilled health workers for
administration or cold chain storage, these products re-
main in development. In addition, problems with the
quality of the oxytocin product available have been iden-
tified in some settings [9]. A recent study by the Food
and Drugs Authority Ghana highlighted problems with
the quality of oxytocin in that country, finding that the
majority of samples of oxytocin (65.5 %) did not meet
the required standards for quality [9].
Misoprostol is a tablet alternative and has the advan-
tages of being stable at room temperature, easy to ad-
minister, and widely accessible [10], features especially
critical in lower resource settings [8]. In early 2011 mi-
soprostol was added to the World Health Organization’s
Model List of Essential Medicines for the prevention of
PPH as a safe and effective medicine [11].
A recent review article questioned WHO’s decision to
include misoprostol on the WHO Model List of
Essential Medicines on the basis of a lack of evidence
of efficacy [12]. The authors of the review subse-
quently submitted an application to WHO’s 19th Expert
Committee on the Selection and Use of Essential
Medicines in Geneva (April 2013) to have misoprostol
for PPH prevention deleted from the Model List of
Essential Medicines on the basis of the poor quality
of the evidence [13]. While there is some heterogeneity
and potential for bias in the published misoprostol
trials, there is evidence of a reduction in PPH when
compared with placebo [14]. The decision of the Expert
Committee was to retain misoprostol on the Essential
Medicines List [15].
A recent Cochrane systematic review, Tunçalp [14], of
prostaglandins for preventing postpartum haemorrhage
has compared the efficacy and safety of misoprostol ver-
sus placebo and misoprostol versus oxytocin. Compared
with ten iU injectable oxytocin, 600 μg oral misoprostol
was associated with higher risks of PPH, severe PPH and
use of additional uterotonics. There was a trend towards
a reduced risk of blood transfusion with misoprostol,
but this did not reach statistical significance. Compared
with placebo, 600 μg oral misoprostol was associated
with reduced risks of PPH and blood transfusion. There
was no statistically significant difference between treat-
ments in severe PPH events. More events of shivering
and fever were reported with misoprostol compared with
both oxytocin and placebo. The trials included in the
Tunçalp 2012 review [14] were conducted in both hos-
pital and community settings, under which reported re-
sults might vary.
Differences in the rates of PPH and other outcomes of
interest in various settings can lead to different conclu-
sions regarding the cost-effectiveness of a program of
PPH prevention using misoprostol or oxytocin. The pat-
tern of health resource utilisation associated with a strat-
egy of prevention of PPH differs in the community
compared to hospital settings as well. Existing economic
evaluations for misoprostol in PPH prevention have fo-
cussed on community facilities only [16, 17]. We there-
fore carried out an economic analysis of misoprostol use
for PPH prophylaxis in different settings, drawing on
data from the 2012 Cochrane systematic review [14].
Methods
A cost-consequences analysis was conducted from the
international health system perspective, which presents
the incremental costs, incremental effectiveness and in-
cremental safety associated with misoprostol versus its
comparators, without calculating an incremental cost-
effectiveness ratio. This allows each of the outcomes as-
sociated with the prevention of PPH to be considered
without converting outcomes to a single measure, such
as quality adjusted life years; allowing decision makers
to make their own trade-offs between outcomes [18].
Several options were examined. First, that only oxyto-
cin is available and used in the hospital or health centre
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where skilled birth attendants are trained in the adminis-
tration of intravenous (IV) or intramuscular (IM) oxyto-
cin and appropriate storage and transport facilities are
available. In this scenario, no preventive treatment for
PPH is offered in the community setting. In the second
scenario, oxytocin is used in the hospital or health
centre and misoprostol is used in the community setting.
In the third setting, misoprostol is used in both hospital
and community settings. The latter might be considered
where oxytocin is not available or the quality of the
product supplied cannot be assured.
Two comparisons are presented in the cost conse-
quences analysis - the first assumed that oxytocin would
be used in the hospital setting and misoprostol would be
used in the community setting. For this analysis the
comparator is oxytocin used in the hospital setting and
no treatment offered in the community. The second
analysis assumed that misoprostol would be used in both
hospital and community settings. For this comparison,
the comparator is no treatment in either hospital or
community settings.
For both analyses, the base case assumed that 40 % of
births occur in the hospital/health centre setting and
60 % of births occurred in the community setting. These
proportions were varied in sensitivity analyses.
The primary outcome of interest was PPH events, de-
fined as blood loss ≥500 mL. Severe PPH was defined as
blood loss ≥1000 mL. Use of additional uterotonics, need
for blood transfusion, shivering and fever were also in-
cluded in the analyses. To simplify the analyses, and due
to a lack of evidence of a difference between treatments,
several outcomes (and their associated costs) were not
included in the analyses: maternal death, hysterectomy,
manual removal of placenta, nausea, vomiting and diar-
rhoea. The baseline event rates without treatment and
with oxytocin treatment were obtained from the most
recent Cochrane systematic review, Tunçalp [14] (pla-
cebo rates from the misoprostol 600 μg versus placebo
comparison; oxytocin rates from the misoprostol 600 μg
versus injectable uterotonics comparison) (Table 1), as
were the relative risks of misoprostol compared with
placebo and oxytocin (Table 2). Where relative risks
(and their 95 % confidence intervals) were not generated
in Tunçalp [14] due to heterogeneity, these were gener-
ated for the analysis using the random effects model in
StatsDirect (Version 2.7.8, 2010), so that incremental
outcomes and costs could be calculated. Numbers of
events were based on a cohort size of 1000 women and
derived by multiplying the baseline event rates for each
outcome by the relative risks associated with each treat-
ment option.
Resource use associated with PPH treatment was
based on WHO’s Mother-Baby Package Costing Spread-
sheet [19]. The Spreadsheet and accompanying Users’
Manual developed by WHO is a tool for estimating the
cost of implementing a set of interventions at the district
level to reduce maternal and newborn mortality and
morbidity. The clinical management of PPH summarised
from the Spreadsheet Users’ Manual is presented in
Table 3. According to the WHO Mother-Baby Package,
the treatment of PPH consists of IM/IV oxytocin imme-
diately after delivery, uterine massage, catheterisation of
the bladder if necessary, repair of tears, fluids and blood
transfusion, and referral as necessary. Health posts
(staffed by auxiliary workers) should refer all cases to a
higher level in the health system following initiation of
treatment. Health centres (staffed by at least one doctor,
professional nurse or midwife) are assumed to refer ap-
proximately half of their cases to the hospital.
The resources included are uterotonics for the preven-
tion of PPH (misoprostol or oxytocin), IV fluids, injec-
tion set, and extra days in hospital, emergency transport,
additional uterotonics, and blood transfusion (Table 4).
Bladder catheterisation and repair of tears is not in-
cluded in the costing of this analysis. The unit price of
Table 1 Baseline event rates used in the economic evaluation
Baseline incidence Point estimate Low High
Placebo event rates (Tunçalp [14])
PPH 16.0 % 12.0 % 27.3 %
Severe PPH 3.0 % 0.7 % 9.7 %
Additional uterotonics 7.2 % 0.7 % 38.7 %
Blood transfusion 0.8 % 0.5 % 0.9 %
Shivering 10.8 % 0.0 % 17.3 %
Fever 1.6 % 0.0 % 4.3 %
Oxytocin event rates (Tunçalp [14])
PPH 12.4 % 0.4 % 17.3 %
Severe PPH 2.7 % 0.0 % 6.5 %
Additional uterotonics 11.1 % 4.4 % 14.0 %
Blood transfusion 1.1 % 0.0 % 1.6 %
Shivering 6.0 % 0.0 % 40.4 %
Fever 1.0 % 0.00 % 7.00 %
Placebo event rates; alternative values: home birth setting (Hundley [23])
PPH 12.2 % NC NC
Severe PPH 1.2 % NC NC
Additional uterotonics 5.4 % NC NC
Blood transfusion 2.9 % NC NC
Shivering 17.8 % NC NC
Fever 13.8 % NC NC
Abbreviations: NC not calculated. Placebo event rates from Tunçalp [14] based
on the misoprostol 600 μg vs placebo comparison; oxytocin event rates from
the misoprostol 600 μg vs injectable uterotonics comparison. Point estimates
derived from an average across all trials; Low values derived from the trial
with the lowest estimate; High values derived from the trial with the
highest estimate
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oxytocin and misoprostol were derived from the Inter-
national Drug Price Indicator Guide, published by
Management Sciences for Health (MSH) (Table 4) [20].
The effective doses used in the analysis are 600 μg miso-
prostol tablet and ten iU oxytocin administered IV or
IM. The costs associated with side effect management,
such as shivering and fever, are likely to be small [16]
and frequently do not require treatment [21]; so were
not included in the economic analysis. Other costs ex-
cluded are those that are unlikely to change because of
the interventions – staff time, overhead costs and capital
costs. Costs were estimated based on 2012 US dollars in-
flated using the Consumer Price Index (CPI) Inflation
Calculator provided by the United States (US) Bureau of
Labour Statistics [22].
The non-drug unit costs are based on the costs in the
WHO Mother-Baby Package Costing Spreadsheet from
1999, updated to 2012 US dollars, which may no longer
be appropriate. An ideal source of unit costs for the cost
consequences analysis would be a comparative in-
country study with contemporaneous controls that
collects relevant cost data. While such studies are under-
way, decisions on which strategies to adopt for the pre-
vention of PPH are being taken in countries. In the
absence of ideal data, the current study, using inflated
unit costs from the WHO Mother Baby Package, provide
supportive data that can be used to inform decisions
now. In the absence of such estimates, decisions may be
opinion or consensus based.
Various one-way (univariate) sensitivity analyses were
conducted on key parameters including the incidence of
events, cost of drugs and PPH treatment and the pro-
portions of births in the community and hospital set-
tings. The upper and lower confidence limits of the
relative risks of treatment from the results of the system-
atic review Tunçalp [14] were used to substitute the base
case treatment effect. The impact of using results from a
recent review of oral misoprostol in preventing PPH in
the home birth setting was also tested in a sensitivity
analysis [23]. Where outcomes were not included in this
review (severe PPH, need for blood transfusion), results
were generated for the analyses presented here based on
the studies included in the review using the random ef-
fects model in StatsDirect (Version 2.7.8, 2010) [24–26].
The effects of halving and doubling the treatment costs
of PPH on the conclusions were also assessed. The ana-
lyses were conducted in Microsoft Excel 2007.
Table 2 Relative risks used in the model
Comparison Point estimate Low High
RR misoprostol vs oxytocin (Tunçalp [14])
PPH 1.43 1.34 1.52
Severe PPH 1.36 1.17 1.58
Additional uterotonics 1.35 1.1 1.66
Blood transfusion 0.77 0.59 1.02
Shivering 2.94 2.35 3.67
Fever 6.77 5.55 8.27
RR misoprostol vs placebo (Tunçalp [14])
PPH 0.77 0.6 0.99
Severe PPH 0.91 0.51 1.63
Additional uterotonics 0.86 0.66 1.13
Blood transfusion 0.24 0.06 0.94
Shivering 3.01 2.68 3.39
Fever 5.39 3.78 7.69
RR misoprostol vs placebo alternative values (Hundley [23])
PPH 0.58 0.38 0.87
Severe PPH 0.2 0.04 0.91
Additional uterotonics 0.34 0.16 0.73
Blood transfusion 0.16 0.07 0.38
Shivering 2.18 1 4.72
Fever 1.4 0.16 12.09
Abbreviations: RR relative risk, PPH postpartum haemorrhage. Low values are
the lower 95 % confidence limit; High values are the upper 95 % confidence
limit from the relevant review
Table 3 Clinical management of postpartum haemorrhage
Component Health post Health centre Hospital
Treatment - - IM/IV oxytocin immediately after delivery; - IM/IV oxytocin immediately after delivery;
- uterine massage; - uterine massage;
- catheterisation of bladder if necessary; - catheterisation of bladder if necessary;
- repair of tears; and - repair of tears;
- fluids - fluids and
- blood transfusion
No. hospital days - 50 % will require 2 days 50 % will require 7 days
Referral 100 %: 50 % to health centre; 50 %
to hospital
50 % to hospital -
Source: WHO Mother-Baby Package Costing Spreadsheet Users’ Guide [20]
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Results
In the base case estimation (Table 5), it was assumed
that 40 % of births would occur in the hospital/health
centre setting and 60 % in the community.
Using oxytocin in the hospital setting and misoprostol
in the community setting instead of oxytocin in the
hospital setting and no treatment in the community set-
ting, 22 cases of PPH could be prevented in the cohort
of 1000 women. There would be two fewer cases of
severe PPH, six fewer women requiring additional utero-
tonics and four fewer women would need a blood trans-
fusion. An additional 130 women would experience
shivering and 42 women fever. Compared with oxytocin/
no treatment, oxytocin/misoprostol was cost saving
(US$320; comprising US$162 in extra drug costs, and
savings of US$482 associated with treating fewer cases
of postpartum haemorrhage).
Similar but more favourable results are obtained if mi-
soprostol is used for all women in the cohort of 1000
births instead of placebo/no treatment in both the
hospital and community settings, where oxytocin is not
available. Thirty seven cases of PPH could be prevented,
there would be three fewer cases of severe PPH, ten
fewer women would need additional uterotonics and six
fewer women would require a blood transfusion. An
additional 217 women would experience shivering and
an extra 70 women fever. Using misoprostol in the hos-
pital and community setting would be cost saving
(US$533; comprising US$270 in extra drug costs, and
US$803 in cost offsets associated with treating fewer
cases of PPH).
Table 6 shows the effect of various changes to key pa-
rameters used in the economic evaluation for the sce-
nario where oxytocin is used in hospital and misoprostol
Table 4 Costs used in the model
Costs (2012 US$) Point estimate Low High Source
Oxytocin/10 iU $0.2184 0.0368 0.7289 MSH [21]
Misoprostol/200 μg $0.09 0.0564 0.1786 MSH [21]
IV fluids $1.79 0.895 3.58 WHO [20]
Infusion-giving set $0.32 0.16 0.64 WHO [20]
Unit of blood $41.67 20.835 83.34 WHO [20]
Blood giving set $0.48 0.24 0.96 WHO [20]
Emergency transport $0.41/km 0.205 0.82 WHO [20]
Overnight in health centre $1.39 0.695 2.78 WHO [20]
Overnight in hospital $3.47 1.735 6.94 WHO [20]
Syringe $0.07 0.035 0.14 WHO [20]
Costs from the WHO Mother-baby package [20] inflated to 2012 US$ [23]; low values are the point estimates multiplied by 0.5; high values are the point estimates
multiplied by 2
Table 5 Economic analysis: outcomes in a cohort of 1000 births where oxytocin is and is not available in the hospital setting
Scenario Oxytocin available in hospital setting Oxytocin not available
hospital/community Oxytocin/Misoprostol Oxytocin/No treatment Increment Misoprostol No treatment Increment
Efficacy
PPH 124 146 −22 123 160 −37
Severe PPH 27 29 −2 27 30 −3
Additional uterotonics 82 88 −6 62 72 −10
Blood transfusion 6 9 −4 2 8 −6
Safety
Shivering 219 89 130 325 108 217
Fever 56 14 42 86 16 70
Cost
Drugs for prevention $249 $87 $162 $270 $0 $270
Treatment of PPH $2 383 $2 865 -$482 $1 968 $2 770 -$803
Total Cost $2 633 $2 952 -$320 $2 238 $2 770 -$533
Results are rounded to the nearest whole number. Currency is 2012 US$. Calculations based on 40 % of births occurring in the hospital setting and 60 % in the
community setting
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in community. When using the higher confidence limits
of the relative risks for misoprostol versus placebo, only
one case of PPH is avoided by using misoprostol in the
community and there are additional costs of US$645.
Using the relative risks from the recent trials in home
birth settings in the Hundley [23] systematic review, the
results were more favourable for misoprostol, with more
cases of PPH averted (31), fewer side effects (an
additional 126 cases of shivering and 33 cases of fever)
and greater cost savings ($1477), compared with the
base case. Using the higher drug costs in the MSH Inter-
national Drug Price Indicator Guide [20], misoprostol
use in the community is no longer cost saving, and is as-
sociated with additional costs of US$151.
Table 7 summarises the impact of varying the propor-
tion of births that occur in the hospital versus commu-
nity settings. A higher proportion of births in the
community setting resulted in fewer cases of PPH and
greater savings associated with misoprostol use, but
higher numbers of side effects.
Discussion
The economic analysis of oxytocin/misoprostol versus
oxytocin/no treatment in a mixed clinical setting (40 %
hospital/60 % community) demonstrates that a miso-
prostol prevention strategy can reduce the number of
women with PPH, but would result in a large number of
women experiencing fever and shivering. The results of
the economic analysis are dependent on the proportion
of births that occur in hospital compared to the commu-
nity, as well as drug and PPH treatment costs.
In this study, we incorporated data from the recent
Cochrane systematic review [14], international drug
prices [20] and the WHO mother-baby costing spread-
sheet [19] to provide an economic evaluation applicable
in the international context. Although a recent article
has questioned the results from misoprostol studies con-
ducted in low- and middle-income countries [12], these
studies form the best evidence available and the studies
conducted in low-resource settings are more likely to be
representative of the use of misoprostol in practice.
Table 6 Univariate sensitivity analyses: Incremental outcomes: comparing oxytocin/misoprostol with oxytocin/no treatment in a
cohort of 1000 births
Sensitivity analysis PPH Severe PPH Additional uterotonics Blood transfusion Shivering Fever Total Cost
Base Case −22 −2 −6 −4 130 42 -$320
Lower bound of RRa −38 −9 −15 −5 109 27 -$792
Higher bound of RRa −1 11 6 0 155 64 $645
Lower cost of drugs −22 −2 −6 −4 130 42 -$377
Higher cost of drugs −22 −2 −6 −4 130 42 $151
50 % treatment cost −22 −2 −6 −4 130 42 -$81
200 % treatment cost −22 −2 −6 −4 130 42 -$798
Health centre $20; hospital $50/night −22 −2 −6 −4 130 42 -$1 053
Misoprostol vs placebo RR and placebo baseline risks from Hundley [23]
Mean −31 −6 −21 −15 126 33 -$1 477
Lower bound of RRb −45 −7 −27 −16 0 −70 -$1 729
Higher bound of RRb −10 −1 −9 −11 397 918 -$824
aLower and upper 95 % confidence limits for the misoprostol versus placebo relative risks from Tunçalp [14]
bLower and upper 95 % confidence limits for the misoprostol versus placebo relative risks from Hundley [23]
Table 7 Sensitivity analyses varying proportion of births in hospital/community: Incremental outcomes (oxytocin/misoprostol minus
oxytocin/no treatment) applied to 1000 births
% births in hospital/% births in community PPH Severe PPH Additional uterotonics Blood transfusion Shivering Fever Total Cost
0/100 % −37 −3 −10 −6 217 70 -$533
20/80 % −29 −2 −8 −5 174 56 -$426
40/60 % (base case) −22 −2 −6 −4 130 42 -$320
60/40 % −15 −1 −4 −2 87 28 -$213
80/20 % −7 −1 −2 −1 43 14 -$107
100/0 % 0 0 0 0 0 0 $0
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The sensitivity analyses show that the price of PPH
prophylaxis is important. If the costs of misoprostol and
oxytocin are set at the higher end listed by MSH
(US$0.1786/200 μg misoprostol and US$0.7289/10 iU
oxytocin) [20], there are no longer cost savings associ-
ated with misoprostol; there would be an additional cost
of US$151 for the prevention of 22 cases of PPH under
the hypothetical scenario of 40 % hospital births and
60 % community births. A dose of 600 μg (3 tablets of
200 μg) misoprostol was used in this economic analysis
because this is the dosage in the WHO recommenda-
tions for the prevention and treatment of postpartum
haemorrhage [4] and the clinical data were mainly from
600 μg trials [14, 23]. However, the Tunçalp [14] review
suggests that a lower dose of misoprostol (400 μg orally)
shows promising results against placebo. Furthermore,
as misoprostol side-effects are dose-related [27], use of a
lower dose might result in fewer shivering and fever
events. The cost-effectiveness of misoprostol is therefore
likely to be improved if a lower dose is widely accepted
and adopted into clinical practice guidelines.
When using the higher confidence limits of the rela-
tive risks for misoprostol versus placebo, 11 more cases
of severe PPH were associated with using misoprostol
despite a reduction in the number of PPH events (by
one). This inconsistent result might be partially ex-
plained by the heterogeneity of the trial results. It has
been noted [14, 21] that the earlier placebo-controlled
misoprostol trials [28–30] did not indicate any reduction
in severe PPH compared to placebo, while the more re-
cent trials in Gambia [31], India [24] and Pakistan [32]
demonstrated a statistically significant protective effect
of misoprostol on severe PPH. These results are consist-
ent with those from the Hundley [23] review in the
home birth setting which show a statistically significant
reduction in severe PPH for misoprostol compared with
placebo. The results of sensitivity analyses using the
baseline event rates and relative risk results from
Hundley (2013) show a reduction in severe PPH of
between one and seven per 1000 women (Table 6).
While there are concerns about the lower effectiveness
and safety of misoprostol compared with oxytocin [14],
some attention has been given to advance distribution of
misoprostol to pregnant women for self-administration
following childbirth. It has been argued this strategy has
the potential to save lives where no uterotonic coverage
exists, but also risks inadvertent use before birth or for
other indications, notably abortion [21]. While the com-
parative benefits and risks of this strategy have not been
formally assessed in clinical trials, several observational
studies have concluded that community-based education
and distribution of misoprostol to pregnant women is safe,
acceptable and feasible in low-resource settings [33–35].
Our findings confirm that when oxytocin is available in
hospital/health centre settings, misoprostol is not an
optimum choice in PPH; while in the community setting,
misoprostol could be an effective and cost-saving choice.
It needs to be emphasized that misoprostol does not have
the same requirements as oxytocin for cold chain storage,
sterile equipment, and personnel skilled in parenteral ad-
ministration. In low-resource settings, a large proportion
of births occur in the community setting without profes-
sionally trained attendants [8]. Misoprostol may therefore
be the only available option in the community setting and
other settings where there is a lack of appropriate health
resources and no access to the more effective treatment
option, oxytocin.
The best information for decision making will come
from studies conducted in country, i.e. that take account
of the context and specific factors that influence the de-
livery of care. However such studies are resource inten-
sive and not feasible in many settings. In addition,
reliable local cost data may not be readily available for
such analyses. The approach used here offers an alterna-
tive to aid decision making that takes account of the best
available clinical data. The results do not propose a
course of action but inform decision makers of the bene-
fits, harms and financial implications of different policy
approaches. Sensitivity analyses allow the assessment of
the implications of different estimates of effectiveness,
harms and costs.
The results of this study need to be interpreted in the
light of possible limitations. The first limitation was that
for pragmatic purposes, where meta-analysis results
were not reported in Tunçalp 2012 due to study hetero-
geneity, we derived relative risks (and associated 95 %
confidence intervals) using the random effects model.
Although the random effects model allows for treatment
effects to vary across studies, the presence of substantial
heterogeneity may mean that it is not appropriate to
combine the results of all of these trials. Second, the ma-
jority of the resource use and cost data were based on
the WHO Mother-Baby Package issued in 1999 [19],
which may no longer be appropriate, despite the monet-
ary values being inflated to 2012 US dollars. In the ab-
sence of more recent estimates, sensitivity analyses
halving and doubling the cost estimates were conducted;
the misoprostol scenario remained cost saving (US$81
to US$798). Further, the analysis could be easily adapted
to different settings using local resource use and costs.
The analysis does not include mortality due to PPH, be-
cause of a lack of data, and the quality of life of patients
was not considered. Use of misoprostol is associated
with uncomfortable side effects (shivering and fever) that
are not associated with the use of oxytocin. Alfirevic et
al. [36] noted that if used routinely for PPH prevention,
misoprostol would be given to very large numbers of
women, even though many of them (>90 %) would not
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experience PPH and therefore not benefit from the drug
but be at risk of side effects.
Conclusions
Oxytocin remains the gold standard treatment for the pre-
vention of PPH but the medicine may not be available and
of assured quality in some settings. Based on the best
available clinical evidence and economic data, this analysis
has demonstrated that use of oral misoprostol in a mixed
hospital/community setting can reduce the number of
women with PPH and save money. The strategy reduces
the numbers of women requiring additional uterotonics
and blood transfusions, with cost savings from fewer cases
of PPH offsetting the additional costs of misoprostol.
These benefits need to be weighed against the large num-
ber of additional cases of shivering and fever, although
these tend to be mild and self-limiting. The balance of
hospital and community births, the cost of misoprostol
and the costs of treating PPH will influence the economic
decision in different countries.
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